A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.

Saved in:
Bibliographic Details
Title: A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Authors: Hughes BGM; Department of Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia; Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Electronic address: brett.hughes@health.qld.gov.au., Guminski A; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia., Bowyer S; Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia., Migden MR; Departments of Dermatology and Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Schmults CD; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Khushalani NI; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida., Chang ALS; Department of Dermatology, Stanford University School of Medicine, Redwood City, California., Grob JJ; Aix Marseille University, Hôpital de la Timone, Marseille, France., Lewis KD; University of Colorado Denver Cancer Center, Aurora, Colorado., Ansstas G; Department of Surgical Oncology, Washington University School of Medicine, St Louis, Missouri., Day F; Department of Medical Oncology, Calvary Mater Newcastle, Newcastle, New South Wales, Australia., Ladwa R; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Princess Alexandra Hospital, Woolloongabba, Queensland, Australia., Stein BN; Adelaide Cancer Centre, Adelaide, South Australia, Australia., Muñoz Couselo E; Department of Medical Oncology, Melanoma and Other Skin Tumors Unit, Vall d'Hebron University Hospital, Barcelona, Spain., Meier F; Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases, Dresden, Germany., Hauschild A; Department of Dermatology, University Hospital (UKSH), Kiel, Germany., Schadendorf D; Department of Dermatology, University Hospital of Essen, Essen, Germany; German Cancer Consortium, Partner Site Essen, NCT-West, Campus Essen and University Alliance Ruhr, Research Center One Health, University Duisburg-Essen, Essen, Germany., Basset-Seguin N; Hôpital Saint-Louis, Paris, France., Modi B; Division of Dermatology, Department of Surgery, City of Hope, Duarte, California., Dalac-Rat S; Hospital Center University Dijon Bourgogne, Dijon, France., Dunn LA; David H. Koch Center for Cancer Care, Memorial Sloan Kettering Cancer Center, New York, New York., Flatz L; University Hospital Tübingen, Tübingen, Germany., Mortier L; Centre Hospitalier Régional Universitaire de Lille (CHRU), Lille, France., Guégan S; Department of Dermatology, Hôpital Cochin, Paris, France., Heinzerling LM; Department of Dermatology, LMU University Hospital Munich, Munich, Germany; Department of Dermatology, University Hospital Erlangen, Erlangen, Germany., Mehnert JM; Melanoma and Cutaneous Medical Oncology, Perlmutter Cancer Center, NY University, Langone Health, New York, New York., Trabelsi S; CHU de Grenoble - Hôpital A Michallon, Grenoble, France., Soria-Rivas A; Ramón y Cajal University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain., Stratigos AJ; First Department of Dermatology-Venereology, Andreas Sygros Hospital, Athens, Greece; National and Kapodistrian University of Athens Medical School, Athens, Greece., Ulrich C; Charite-Universitatsmedizin Berlin, Berlin, Germany., Wong DJ; UCLA Department of Medicine, Los Angeles, California., Beylot-Barry M; Department of Dermatology, University Hospital of Bordeaux, Bordeaux, France., Bossi P; Department of Biomedical Sciences, Humanitas University, Milan, Italy; IRCCS Humanitas Research Hospital, Milan, Italy., Bugés Sánchez C; Department of Medical Oncology, Skin Tumors Unit, Catalan Institute of Oncology, Germans Trias i Pujol University Hospital, Barcelona, Spain; Badalona-Applied Research Group in Oncology (B-ARGO), Badalona, Barcelona, Spain., Chandra S; Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois., Robert C; Gustave Roussy Cancer Center, Villejuif, France., Russell JS; Head and Neck/Cutaneous Medical Oncology, Huntsman Cancer Institute, Salt Lake City, Utah., Silk AW; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Booth J; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Yoo SY; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Seebach F; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Lowy I; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Fury MG; Regeneron Pharmaceuticals, Inc., Tarrytown, New York., Rischin D; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2025 Jan; Vol. 92 (1), pp. 68-77. Date of Electronic Publication: 2024 Sep 07.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-6787
DOI:10.1016/j.jaad.2024.06.108